Maqui Berry Extract and Omega-3 Fatty Acids for Cytokine Reduction
Beneficial Effects of Maqui Berry Extract Combination With Omega-3 Fatty Acids on Cytokine Reduction in Elderly Obese Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Carol S Johnston, PhD
- Phone Number: 6024962539
- Email: carol.johnston@asu.edu
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Arizona State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females 50-85 years old
- Generally healthy, non-smoker
- Able to provide informed consent
- BMI: 30-40 kg/m2
Exclusion Criteria:
- Existing auto-immune conditions
- Use of warfarin or other blood thinners
- Use of anti-inflammatory drugs, cardiovascular medications, lipid-altering drugs, and hormone replacement therapy
- Individuals engaged in vigorous exercise (>2 x 30 min/week), vegetarians, and people who routinely take multivitamins or herbal supplements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Maqui berry extract and omega-3 fatty acids
2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
|
2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
|
|
Placebo Comparator: Control
4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
|
4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interleukin-6 (IL-6)
Time Frame: change from baseline at day 56
|
Blood concentrations of IL-6
|
change from baseline at day 56
|
|
Interleukin-1 beta (IL-1 beta)
Time Frame: change from baseline at day 56
|
Blood concentration of IL-1 beta
|
change from baseline at day 56
|
|
Tumor Necrosis Factor (TNF)
Time Frame: change from baseline at day 56
|
Blood concentration of TNF
|
change from baseline at day 56
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arachidonic acid (AA)
Time Frame: change from baseline at day 56
|
Blood concentration of AA
|
change from baseline at day 56
|
|
Eicosapentaenoic acid (EPA)
Time Frame: change from baseline at day 56
|
Blood concentration of EPA
|
change from baseline at day 56
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00014007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.